Therefore, this analysis aimed to search for possible predictors of probiotics’ influence on non-invasive biomarkers of liver steatosis and fibrosis among inflammation and metabolic parameters; intestinal permeability biomarkers—such as intestinal fatty acid-binding protein (I-FABP/FABP-2); microbiota metabolites—such as blood short-chain fatty acids (bSCFAs); or dietary habits. The gene discussed is FABP2; the disease is fatty liver disease.